1. Home
  2. FIGS vs IMNM Comparison

FIGS vs IMNM Comparison

Compare FIGS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FIGS Inc.

FIGS

FIGS Inc.

HOLD

Current Price

$13.10

Market Cap

2.1B

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$24.11

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIGS
IMNM
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FIGS
IMNM
Price
$13.10
$24.11
Analyst Decision
Hold
Strong Buy
Analyst Count
7
10
Target Price
$15.93
$32.80
AVG Volume (30 Days)
2.4M
790.2K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
850.00
51.40
EPS
0.18
N/A
Revenue
$419,591,000.00
$6,941,000.00
Revenue This Year
$14.09
N/A
Revenue Next Year
$7.72
$1,127.34
P/E Ratio
$72.56
N/A
Revenue Growth
59.47
N/A
52 Week Low
$6.50
$9.36
52 Week High
$17.48
$30.06

Technical Indicators

Market Signals
Indicator
FIGS
IMNM
Relative Strength Index (RSI) 44.04 36.10
Support Level $12.88 $19.03
Resistance Level $13.17 $25.07
Average True Range (ATR) 0.60 1.01
MACD -0.29 -0.52
Stochastic Oscillator 14.82 5.26

Price Performance

Historical Comparison
FIGS
IMNM

About FIGS FIGS Inc.

FIGS Inc is a healthcare apparel company. It designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other healthcare apparel. The company sells products mainly through its direct-to-consumer (DTC) digital platform, consisting of its website, mobile app, and B2B business (TEAMS). It also operates physical retail stores, which are called Community Hubs, providing a retail experience for healthcare professionals. The company generates maximum revenue from the sale of scrubwear products. Geographically, it derives maximum revenue from the United States, followed by the rest of the world.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: